Leukemia, Myeloid, Chronic-Phase
"Leukemia, Myeloid, Chronic-Phase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
| Descriptor ID |
D015466
|
| MeSH Number(s) |
C04.557.337.539.250.400 C15.378.190.636.370.400
|
| Concept/Terms |
Leukemia, Myeloid, Chronic-Phase- Leukemia, Myeloid, Chronic-Phase
- Granulocytic Leukemia, Chronic, Stable-Phase
- Leukemia, Granulocytic, Chronic Phase
- Leukemia, Granulocytic, Chronic-Phase
- Leukemia, Myelogenous, Chronic Phase
- Leukemia, Myelogenous, Chronic-Phase
- Leukemia, Myeloid, Chronic Phase
- Leukemia, Myeloid, Stable Phase
- Leukemia, Myeloid, Stable-Phase
- Myelogenous Leukemia, Chronic, Chronic Phase
- Myelogenous Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Chronic Phase
- Myeloid Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Stable-Phase
- Granulocytic Leukemia, Chronic, Stable Phase
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Chronic-Phase".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Leukemia, Myeloid, Chronic-Phase [C04.557.337.539.250.400]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Leukemia, Myeloid, Chronic-Phase [C15.378.190.636.370.400]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Chronic-Phase".
This graph shows the total number of publications written about "Leukemia, Myeloid, Chronic-Phase" by people in this website by year, and whether "Leukemia, Myeloid, Chronic-Phase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myeloid, Chronic-Phase" by people in Profiles.
-
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69.
-
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578.
-
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 05; 30(5):1044-54.
-
Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions. Cancer Genet. 2015 Jul-Aug; 208(7-8):396-403.
-
Is there a best TKI for chronic phase CML? Hematology Am Soc Hematol Educ Program. 2015; 2015:250-6.
-
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11.
-
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
-
Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54.
-
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
-
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.